Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

Company Performance - Keros Therapeutics reported a quarterly loss of $0.76 per share, which was better than the Zacks Consensus Estimate of a loss of $1.14, and an improvement from a loss of $1.25 per share a year ago, representing an earnings surprise of +33.33% [1] - The company posted revenues of $18.17 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 135.95%, compared to revenues of $0.04 million in the same quarter last year [2] - Over the last four quarters, Keros Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Keros Therapeutics shares have declined approximately 9.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.08 on revenues of $4.37 million, and for the current fiscal year, it is $0.21 on revenues of $219 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Keros Therapeutics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Keros Therapeutics may be influenced by the overall outlook of the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]